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Background: Australians living in rural areas have lower incidence rates of renal replacement therapy and poorer
dialysis survival compared with urban dwellers. This study compares peritoneal dialysis (PD) patient characteristics
and outcomes in rural and urban Australia.
Methods: Non-indigenous Australian adults who commenced chronic dialysis between 1 January 2000 and 31
December 2010 according to the Australia and New Zealand Dialysis and Transplant Registry (ANZDATA) were
investigated. Each patient’s residence was classified according to the Australian Bureau of Statistics remote area
index as major city (MC), inner regional (IR), outer regional (OR), or remote/very remote (REM).
Results: A total of 7657 patients underwent PD treatment during the study period. Patient distribution was 69.0%
MC, 19.6% IR, 9.5% OR, and 1.8% REM. PD uptake increased with increasing remoteness. Compared with MC,
sub-hazard ratios [95% confidence intervals] for commencing PD were 1.70 [1.61-1.79] IR, 2.01 [1.87-2.16] OR, and
2.60 [2.21-3.06] REM. During the first 6 months of PD, technique failure was less likely outside MC (sub-hazard ratio
0.47 [95% CI: 0.35-0.62], P < 0.001), but no difference was seen after 6 months (sub-hazard ratio 1.05 [95% CI:
0.84-1.32], P = 0.6). Technique failure due to technical (sub-hazard ratio 0.57 [95% CI: 0.38-0.84], P = 0.005) and
non-medical causes (sub-hazard ratio 0.52 [95% CI: 0.31-0.87], P = 0.01) was less likely outside MC. Time to first
peritonitis episode was not associated with remoteness (P = 0.8). Patient survival while on PD or within 90 days of
stopping PD did not differ by region (P = 0.2).
Conclusions: PD uptake increases with increasing remoteness. In rural areas, PD technique failure is less likely
during the first 6 months and time to first peritonitis is comparable to urban areas. Mortality while on PD does not
differ by region. PD is therefore a good dialysis modality choice for rural patients in Australia.
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Among non-indigenous Australians, the incidence of
renal replacement therapy and survival on dialysis are
lower in rural compared with urban areas [1]. Peritoneal
dialysis (PD) prevalence in Australia has fallen from 27%
in 2000 [2] to 21% in 2009 [3]. However, the uptake of
PD among dialysis patients living in rural areas of
Australia [1] and USA [4,5], and Canadians living more
than 50km from the treating nephrologist [6], has been
shown to be higher than urban dwellers.
The impact of rural residence on PD outcomes is
less well understood, particularly outside North America.* Correspondence: Nicholas_Gray@health.qld.gov.au
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reproduction in any medium, provided the orCanadian patients living more than 50 km from their
treating nephrologist were less likely to suffer technique
failure and transfer to haemodialysis (HD), but suffered
increased mortality [6]. A smaller study from Ontario,
Canada did not show a difference in technique failure
or mortality with PD in rural areas [7]. In the USA, rural
PD patients have a higher mortality risk than those in
urban areas [5]. In Australia, technique failure, peritonitis
and mortality have been shown to be higher among re-
mote living indigenous PD patients compared with ur-
ban dwellers [8]. Time to the first episode of peritonitis
among Australian PD patients living more than 100km
from the treating centre is shorter than those living within
100km [9]. Different management practices for peritonitis
for patients living distant to the treating centre have also
been reported [9].
Many studies have examined distance from the trea-
ting centre rather than rural residence per se. However,d. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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with multiple poor health outcomes [10]. This paper de-
scribes non-indigenous PD patient characteristics, com-
plications, and outcomes in rural Australia.
Methods
The Australia and New Zealand Dialysis and Transplant
Registry (ANZDATA) collects observational data on all
patients receiving chronic renal replacement therapy
in Australia. All data are collected and submitted to
ANZDATA by the treating nephrologist or renal health
team at each local site. This study included all non-
indigenous patients aged > =18 years registered with
ANZDATA, who commenced renal replacement ther-
apy between 1 January 2000 and 31 December 2010,
and underwent PD at some stage during this period
in Australia. Indigenous patients (those who self-identify
as Australian Aborigines or Torres Strait Islanders when
asked their racial origin) undertaking PD were excluded
from this analysis because work in this area has already
been completed [8,11].
The Australian Bureau of Statistics used 2006 Census
data to produce the Australian Standard Geographical
Classification of remoteness areas [12]. This classifies all
statistical local areas according to a remote area index
which is determined by measuring the road distance
from a statistical local area to five classes of service
centre. There are six remote area index classifications:
major city (MC), inner regional, outer regional, remote,
very remote and migratory. Urban areas include the MC
category, while rural areas include regional, remote and
very remote Australia. Where a postcode contained stat-
istical local areas from two or more remote area index
classifications, the postcode was allocated the remote
area index that had the greatest population. Australian
patients without postcode data recorded at commence-
ment of renal replacement therapy were excluded. Pa-
tient numbers in the remote and very remote areas were
small so these groups were combined into a single re-
mote category.
Time to first use of PD was analysed for all patients
who started renal replacement therapy by either conti-
nuous ambulatory PD (CAPD) or automated PD (APD).
The use of icodextrin among PD patients was recorded
during annual surveys in 2007 – 2010. We analysed use
of icodextrin at the survey closest to 1 year after com-
mencing renal replacement therapy for patients who
commenced PD in this period.
Technique failure was defined as any change of moda-
lity from PD to HD that lasted more than 30 days. Rea-
sons for technique failure were only recorded after 2006
and were coded as infectious (related to peritonitis, tun-
nel or exit site infection), technical (dialysate leak, hy-
drothorax, scrotal oedema, catheter difficulties, hernia,pain, surgery, adhesion), dialysis related (ultrafiltration
or solute clearance), non-medical (patient choice for per-
sonal reasons), transplantation, death, and miscellaneous.
The date of first episode of peritonitis was recorded
from 2000, but more detailed data related to periton-
itis (type of organism, treating antibiotics, outcomes
of treatment) was only routinely collected after Octo-
ber 2003. Peritonitis outcomes were classified as reso-
lution of peritonitis with continuation of PD, removal
of Tenckhoff catheter, permanent transfer to HD, and
death within 90 days.
Patient death on PD was defined two ways: death
during PD treatment; and death while on PD or within
90 days of transferring to HD. Patient death following
transplantation but within 90 days of ceasing PD was
considered a transplant related death. Causes of death
were categorised into: cardiovascular causes (cardiac
complications, ischaemia, infarction, aneurysms, haemor-
rhage), infectious, non-medical (suicide, withdrawal from
dialysis for any reason, accidental death), malignant or
miscellaneous. Patient survival was analysed using an “as
treated analysis.”
Statistics
All analyses were adjusted for the following factors at
commencement of renal replacement therapy: age ca-
tegory (18–44, 45–54, 55–64, 65+ years), body mass
index category (< 18.49, 18.5-24.9, 25–29.9, 30+ kg/m2),
smoking status, comorbidities (diabetes, chronic lung
disease, coronary artery disease, peripheral vascular di-
sease, cerebrovascular disease), primary kidney disease
(glomerulonephritis, diabetes, hypertension, polycystic,
reflux or others), late referral (commencing renal re-
placement therapy within 3 months of referral to neph-
rology care), gender, race (Caucasian, Asian or other),
and size of initial treating centre. The size of the initial
treating centre was divided based on the number of inci-
dent patients from 2000–2010; small (1–49 patients),
medium (50–199 patients), and large (200+ patients).
Uptake of all forms of PD, as well as patient and tech-
nique failure, and time to first episode of peritonitis were
all analysed using competing risk regressions, using the
methods of Fine and Gray [13]. The assumption of con-
stant proportional sub-hazards was checked by plotting
Shoenfeld-like residuals and by investigating a remote-
ness: time interaction term within the model. For analyses
of PD uptake from time of commencing renal replacement
therapy, death and transplantation were competing risks.
Death, transplantation and APD were competing risks for
CAPD. Death, transplantation and CAPD were competing
risks for APD.
All cause technique failure from the time of commen-
cing PD was analysed with transplantation as a compe-
ting risk. Because the hazard ratio varied over time, this
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Figure 1 Flowchart of patients included in the study.
PD = peritoneal dialysis.
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6 months was examined separately to subsequent failure.
Technique failure due to a specific cause was analysed
with other causes as competing risks. Patients were
encoded as either MC or other when small numbers of
cases were present (individual causes of PD technique
failure and cause of death). Time to first peritonitis epi-
sode analyses included death and transplantation as
competing risks. The incidence of peritonitis was ana-
lysed using Poisson regression, with total time on PD
per patient as an offset.
The outcomes of each case of peritonitis were investi-
gated using mixed-effects logistic regression, with infec-
tion number nested within patient as random effects.
Separate models investigated the proportion of periton-
itis cases that resulted in a permanent change to HD, re-
moval of the peritoneal catheter, or death within 90
days. The use of icodextrin at the survey closest to one
year after commencing renal replacement therapy was
analysed using logistic regression. Specific causes of death
were also compared between remoteness areas using lo-
gistic regression.
Results are presented as either sub-hazard ratios (analo-
gous to hazard ratios from Cox regressions) from com-
peting risk survival models, or odds ratio from logistic
regressions, with 95% confidence intervals [95% CI].
All analysis was carried out using Stata IC 12.1 (Stata-
Corp, College Station, TX, USA). This study was ap-
proved by the Prince Charles Hospital human research
ethics committee.Results
Figure 1 shows a flow chart of the study population. PD
patient distribution was 69.0% MC, 19.6% inner regional,
9.5% outer regional, and 1.8% remote. Patient character-
istics at commencement of renal replacement therapy
are shown in Table 1. Diabetic kidney disease was more
common in MC while current smoking, chronic lung
disease, obesity and Caucasian race were more common
among patients from rural areas.
The uptake of PD increased with increasing remote-
ness (Figure 2). However, among patients who ever used
PD, patients from outer regional and remote areas were
less likely to commence renal replacement therapy with
PD (Table 1). Compared with MC, sub-hazard ratios
[95% confidence intervals] for uptake of PD after ad-
justment for age, gender, body mass index, smoking, co-
morbidities, late referral, race, and centre size were 1.70
[1.61-1.79] inner regional, 2.01 [1.87-2.16] outer regio-
nal, and 2.60 [2.21-3.06] remote. This was largely due to
increasing uptake of APD, although CAPD also in-
creased with remoteness. Use of icodextrin did not vary
significantly with remoteness (P = 0.9).Technique failure rates in rural areas were low so
inner regional, outer regional and remote patients were
grouped. Overall technique failure was less likely during
the first 6 months of PD for this rural group compared
with MC after adjusting for other variables, but tech-
nique failure was not associated with remoteness after 6
months of PD (Figure 3). Patients living outside major
cities were less likely to be transferred to HD due to
technical or non-medical causes (Table 2).
There were 5159 cases of peritonitis over 9328 person-
years at risk, giving a rate of 0.55 cases per year. Time to
first peritonitis episode did not vary with remoteness
(P = 0.8), but total peritonitis cases per year did (Table 1).
Compared to small centres, medium-sized centres (50 –
199 incident patients) and large centres (200+ incident
patients) had lower rates of peritonitis (sub-hazard ratio
[95% CI] for time to first peritonitis 0.64 [0.50-0.81],
P < 0.001; and 0.60 [0.45-0.74], P < 0.001 respectively).
Patients living outside major cities were more likely to
suffer culture negative or methicillin sensitive Staphylo-
coccus aureus peritonitis (Table 3). Remote patients were
less likely to transfer permanently to haemodialysis after
an episode of peritonitis (Table 4).
Patient survival while on PD or within 90 days of stop-
ping PD did not differ significantly by region overall
(P = 0.2). Cause of death between major cities and grouped
rural areas did not differ for infectious (P = 0.7), non-
medical causes including withdrawal from dialysis for any
reason, accident, or suicide (P = 0.1), or miscellaneous
causes (P = 0.8). There was a trend towards increased
cardiovascular (sub-hazard ratio 1.13 [95% CI: 0.98-1.29],
Table 1 Characteristics of adult non-indigenous Australian patients who commenced renal replacement therapy
(2000–2010) and underwent PD at some stage
Factor Major city Inner regional Outer regional Remote p-value
N 5285 1503 731 138
Age, median (IQR) 63 (50, 72) 64 (52, 71) 64 (52, 72) 64 (51, 72) 0.64
Male 57.8% 57.7% 59.2% 60.9% 0.80
Body mass index (kg/m2) <0.001
Underweight (<18.5) 4.2% 2.5% 3.4% 1.4%
Normal (18.5–24.9) 40.3% 38.9% 37.2% 43.5%
Overweight (25–29.9) 33.9% 34.0% 36.6% 22.5%
Obese (> = 30) 21.6% 24.5% 22.7% 32.6%
Chronic lung disease 13.7% 15.9% 14.1% 21.0% 0.02
Coronary artery disease 34.7% 34.9% 32.1% 33.3% 0.60
Peripheral vascular disease 20.0% 20.7% 17.8% 22.5% 0.30
Cerebrovascular disease 14.3% 15.6% 13.3% 16.7% 0.40
Diabetes 40.2% 32.5% 33.9% 33.3% <0.001
Primary renal disease <0.001
Glomerulonephritis 1422 (26.9%) 430 (28.6%) 184 (25.2%) 34 (24.6%)
Diabetes 1633 (30.9%) 341 (22.7%) 176 (24.1%) 38 (27.5%)
Hypertension 523 (9.9%) 149 (9.9%) 78 (10.7%) 25 (18.1%)
Polycystic 313 (5.9%) 103 (6.9%) 47 (6.4%) 8 (5.8%)
Reflux 243 (4.6%) 75 (5.0%) 26 (3.6%) 6 (4.3%)
Other 1151 (21.8%) 405 (26.9%) 220 (30.1%) 27 (19.6%)
Late referral 21.2% 23.4% 24.2% 25.4% 0.10
Current smoking 10.6% 12.0% 13.7% 14.5% 0.03
Race <0.001
Caucasian 77.4% 97.0% 94.7% 94.2%
Asian 12.9% 1.7% 3.1% 2.2%
Other 9.7% 1.3% 2.2% 3.6%
Creatinine (umol/L) at entry, median (IQR) 631 (490, 827) 635 (490, 813) 673 (536, 855) 729 (540, 910) <0.001
PD at commencement of dialysis 3446 (65.2%) 1002 (66.7%) 433 (59.2%) 82 (59.4%) 0.002
PD facility size (incident patients in study period) <0.001
1–49 patients 139 (2.6%) 86 (5.7%) 53 (7.3%) 26 (18.8%)
50–199 patients 314 (5.9%) 488 (32.5%) 266 (36.4%) 32 (23.2%)
200+ patients 4829 (91.4%) 929 (61.8%) 412 (56.4%) 80 (58.0%)
Peritonitis cases per year (Poisson mean and 95%CI) 0.55 (0.53–0.56) 0.55 (0.51–0.58) 0.59 (0.54–0.64) 0.71 (0.59–0.84) 0.014
Time per patient spent on PD in months, median (IQR) 16.4 (7.1–29.3) 15.8 (7.7–29.3) 17.0 (7.6–27.8) 17.0 (7.8–31.7) 0.81
IQR interquartile range, late referral = commenced dialysis < 3 months from first referral to a nephrologist, PD facility size was categorised by the number of
patients commencing PD during the study period, CI confidence interval.
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0.99-2.27], P = 0.06) deaths in rural areas.
Discussion
This study has shown that among non-indigenous
Australians, the uptake of PD increases with increas-
ing remoteness; time to first peritonitis in rural areas
is comparable with MC; PD technique failure rates inthe first 6 months are lower in rural areas due to less
technical and non-medical causes; and overall death
rates do not vary between regions. There is a sugges-
tion that more cardiovascular and malignant deaths
occur in rural areas.
Incidence rates of renal replacement therapy among
non-indigenous people have previously been shown to
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Figure 2 Uptake of all PD, CAPD and APD over time, by remoteness categories.
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http://www.biomedcentral.com/1471-2369/14/278patients living in remote areas, where regular travel to
HD units is not practical. In addition, PD does not need
large quantities of clean water and/or reliable power
which may limit home haemodialysis as an option for
some rural patients. It is therefore not surprising that
PD uptake increases with remoteness. Our data confirms
findings from other studies [4-6].
Importantly, our data showed no difference in morta-
lity among PD patients across all regions. This is reas-


















Figure 3 Cumulative incidence of technique failure, with transplantat
remote areas have been combined to a single “other” group due to smallsafely undertake PD and not be disadvantaged. Given
the overall increased mortality risk for dialysis patients
in rural Australia [1], these findings suggest PD is a pre-
ferred modality. While these findings are supported by a
Canadian cohort of incident PD patients [7], in the USA
PD patients had higher mortality in micropolitan and
rural areas [5]. The prevalence of PD is much lower in
USA and there are likely many other country specific
and patient selection factors that may explain the dif-
ference. A limitation of our study is that we did not2 3 4
ears
Other
ion and death as competing risks. Inner regional, outer regional and
numbers.
Table 2 Competing risk sub-hazard ratios [95%
confidence intervals] for technique failure, by reason for
failure
Major city All other regions*
All cause – first 6 months 1 (reference) 0.47 [0.35–0.62], P < 0.001
All cause > 6 months 1 (reference) 1.05 [0.84–1.32], P = 0.6
Infection 1 (reference) 1.15 [0.80–1.67], P = 0.5
Dialysis 1 (reference) 1.05 [0.73–1.52], P = 0.8
Technical 1 (reference) 0.57 [0.38–0.84], P = 0.005
Non–medical 1 (reference) 0.52 [0.31–0.87], P = 0.01
Transplantation 1 (reference) 1.12 [0.82–1.53], P = 0.5
*Inner regional, outer regional and remote were grouped due to small
numbers.
Each cause of failure has all other causes and death as competing risks. Data
for reason for technique failure was only available after 2006.
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associated with increased PD patient mortality [6] or
peritonitis risk [9]. Furthermore, our data do not apply
to indigenous patients in rural areas of Australia who
have been shown to have higher mortality rates than
non-indigenous, possibly due to a shorter time to first
peritonitis and that 79% of indigenous in rural Australia
live in remote areas, whereas most non-indigenous in
rural Australia are in regional areas [8].
Technique failure rates in rural areas were lower dur-
ing the first 6 months, similar to Canadian data [6]. In
our cohort this was mainly due to fewer technical and
non-medical reasons for failure. It is understandable that
if a rural patient has a significant distance to travel for
HD there may be greater incentive to persist with PD ra-
ther than abandon for personal reasons. Furthermore,
travel time has been associated with increased mortality
on haemodialysis [14], so it is sensible to continue with
PD when possible. The reason for fewer technical com-
plications causing technique failure in rural PD patientsTable 3 Distribution of agents causing first episode of periton
Major city Inne
Culture negative 257 (14.5%) 103
Coagulase negative Staphylococcus aureus 432 (24.4%) 110
Methicillin resistant Staphylococcus aureus 26 (1.5%) 13 (2
Methicillin sensitive Staphylococcus aureus 138 (7.8%) 38 (7
Other gram positive 307 (17.3%) 77 (1
Gram negative 481 (27.1%) 129
Anaerobes 4 (0.2%) 4 (0.
Fungi 45 (2.5%) 14 (2
Mycobacteria 7 (0.4%) 2 (0.
Other 73 (4.1%) 25 (4
No culture taken 3 (0.2%) 2 (0.
Percentages are for each column and can be > 100% because of multiple organismis uncertain, but may relate to greater persistence in
rural areas to resolve technical problems and continue
PD. Importantly, PD failure for dialysis reasons such
as inadequate clearances or ultrafiltration were similar
between regions, suggesting that dialysis adequacy was
not compromised. Furthermore, although more people
underwent PD, the total duration of PD treatment in
months did not differ by region. PD technique failure
after 6 months did not differ by region, perhaps due
to the greater uptake of PD among rural patients re-
sulting in people less suited to self care commencing
PD than in urban areas.
Time to first episode of peritonitis and peritonitis as a
cause for technique failure were not different by remote-
ness area. We did find a difference in overall peritonitis
rates by region, with higher rates in remote areas in parti-
cular. However, peritonitis data submitted to ANZDATA
for second and subsequent episodes may not be as accur-
ate or complete as for the first episode. Previous work has
shown an increased rate of peritonitis and shorter time to
first peritonitis for patients living >100km from the treat-
ing centre in Australia [9]. It seems that distance from
the treating centre and possibly remote residence is
therefore associated with increased peritonitis rates in
Australia. This may reflect difficulties with home visits
with increased distance and suggests a possible role for
telemedicine.
Our study confirms previous findings [9] that there is
an increased rate of Staphylococcus aureus peritonitis
in rural areas, especially in outer regional and remote
Australia. The causes for this finding are uncertain
but may be affected by higher Staphylococcus aureus
colonisation rates and possibly inadequate decolonisation
procedures in remote areas. Decolonisation with topical
mupirocin has been associated with a 70% reduction in
Staphylococcus aureus peritonitis rates [15].itis, by remoteness area
r regional Outer regional Remote p-value
(19.9%) 42 (16.3%) 9 (16.4%) 0.03
(21.3%) 50 (19.4%) 9 (16.4%) 0.4
.5%) 5 (1.9%) 3 (5.5%) 0.4
.4%) 33 (12.8%) 5 (9.1%) 0.01
4.9%) 37 (14.3%) 7 (12.7%) 0.9
(25.0%) 69 (26.7%) 15 (27.3%) 0.8
8%) 0 (0.0%) 0 (0.0%) 0.04
.7%) 10 (3.9%) 1 (1.8%) 0.6
4%) 2 (0.8%) 0 (0.0%) 0.6
.8%) 10 (3.9%) 5 (9.1%) 0.09
4%) 0 (0.0%) 1 (1.8%) 0.6
s cultured for some patients.
Table 4 Peritonitis outcomes
Major city Inner regional Outer regional Remote
Transfer to haemodialysis 1 (reference) 0.89 [0.73–1.10] P = 0.3 0.91 [0.70–1.18] P = 0.5 0.49 [0.28–0.88] P = 0.02
Catheter removal 1 (reference) 0.93 [0.76–1.14] P = 0.5 0.96 [0.75–1.24] P = 0.8 0.75 [0.45–1.22] P = 0.2
Death within 90 days 1 (reference) 0.94 [0.58–1.53] P = 0.8 1.13 [0.60–2.12] P = 0.7 1.08 [0.32–3. 61] P = 0.9
Data presented are odds ratios [95% confidence intervals] and P values, produced from mixed–effects logistic regression. Models were adjusted for age, body
mass index category, smoking status, comorbidities, primary kidney disease, late referral, gender, race, and size of treating centre, with infection number nested
within patient as random effects.
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in rural areas, those living in outer regional and remote
Australia are less likely to commence dialysis with PD
than in major cities. This finding is different to Canadian
[6] and American [5] data which shows people in remote
areas are more likely to commence dialysis with PD than
city dwellers. However, in USA the uptake of PD at com-
mencement of dialysis was less than 10% of incident pa-
tients, much lower than Australia. The Canadian study
was different to ours because it examined patients com-
mencing dialysis in an earlier time period (1990–2000),
examined distance from the treating nephrologist rather
than rural residence, and included indigenous patients.
The lower dialysis initiation with PD in outer regional
and remote areas was not explained by a difference in
late referral to a nephrologist by remoteness area. How-
ever it remains possible that people in these areas did
not seek nephrology care until late in the course of their
kidney disease, perhaps due to the smaller medical [16]
and nephrology [17] workforces compared with urban
areas.
Our study has several limitations. Postcode data at
commencement of renal replacement therapy was used
and we do not know how many or how often patients
relocate to access health care for kidney disease prior to
commencing dialysis. Socio-economic status was not ex-
amined in this analysis. Previous work has demonstrated
increased PD technique failure with lower neighbour-
hood education level [7]. Furthermore, lower socioecono-
mic status has been associated with increased PD patient
peritonitis and mortality in China [18] and peritonitis as-
sociated hospitalisation and death in Australia [19]. The
method used to classify a postcode by remote area index
relied on data from statistical local areas and some post-
codes had several different remote area index classifica-
tions of statistical local areas. Our classification of each
postcode may thus have created a bias, although to min-
imise this we used the most populous remote area index
allocation for each postcode. There is no data on patients
who were managed conservatively and never commenced
dialysis, although treatment rates have been shown similar
by remoteness [20]. The data is observational and there
are many variables such as exit-site infection, local proto-
cols, use of telehealth, and local available expertise whichare unavailable for this analysis. Lastly, the data collected
by ANZDATA is submitted voluntarily and has only been
subjected to a small audit [21], although all units in
Australia and New Zealand participate and assert that
reporting is complete.
Conclusion
This study has shown an increased uptake of PD with
increasing remoteness in Australia. PD technique failure
rates are lower in rural areas while peritonitis rates and
mortality do not vary by region. PD therefore appears to
be a good treatment choice for patients living in rural
Australia. Efforts to maintain and improve quality care
in rural areas such as adherence to guidelines, use of
outreach clinics and telehealth may further enhance the
health of rural patients.
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